Added to YB: 2026-02-03
Pitch date: 2026-01-30
GSK [bullish]
GSK plc
+19.19%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 86.9B
Pitch Price
GBP 18.68
Price Target
N/A
Dividend
3.33%
EV/EBITDA
7.63
P/E
15.60
EV/Sales
3.08
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 30/1/2026 - GSK – Pipeline progress
GSK (update): Arexvy RSV vaccine approval expanded to all EU adults 18+ (previously 60+ only), seeking similar expansion in US/Japan. Commercially positive development for broader customer base. Trades 9.6x 2027 consensus earnings, 3.8% yield - appears undervalued.
Read full article (1 min)